The company was founded in 2001 based on technology developed at Drexel University College of Medicine. They are working on an investigational new drug application for a serotonin antagonist to be used in a clinical trial for multiple myeloma patients. Immune Control aims to find compounds that can be used against various diseases caused by inappropriate lymphocyte activation, such as type I diabetes, rheumatoid arthritis, and asthma. They also prioritize developing proprietary serotonin antagonists that are more potent and have fewer neurological side effects. The company aggressively protects its intellectual property through patent applications and has licensed the IP portfolio exclusively from Drexel University. Immune Control has merged with Arginetix to form Corridor Pharmaceuticals Inc. and is based in Conshohocken, Pennsylvania.